Exicure, Inc. (XCUR) is a biotherapeutics company engaged in the development of nucleic acid therapeutics for neurological disorders and hair loss. The company’s exclusive Spherical Nucleic Acid architecture has distinct biological and chemical characteristics that are advantageous over other similar therapeutics.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
XCUR stock price during the regular trading session of March 25, 2022, was $0.26 with a major decrease of 16.6%. Its price further nosedived as of the writing in the aftermarket session by 26.9%.
XCUR: Key Financials
XCUR issued its full fiscal year 2021 financial results on March 25, 2022, for the year ended December 31, 2021. Some focal points are discussed below.
The company posted revenue of $0.5 million in FY2021 corresponding to $16.6 million recorded during the corresponding year 2020. Its revenue observed a $16.1 million increase year-over-year.
Net loss basic and diluted during FY 2021 was recorded to be $64.1 million or $0.72 per share in comparison to $24.7 million or $0.28 per share during the comparable year 2020. The company’s net loss increased significantly YoY.
XCUR: Events and Happenings
On February 4, 2022, XCUR updated on the resignation of the President, CEO, and board member Brian C. Bock with immediate effect. The board of directors had appointed Matthias Schroff as the new CEO of the company. He had already served as the company’s Chief Scientific Officer.
On December 14, 2021, XCUR reported about its entry into a definitive contract for the acquisition and sale of its 34,576,068 common stock and warrants with certain institutional investors. The company intended to acquire approximately 17,288,034 common stock shares at a per-share acquisition price of $0.3326 in a registered direct offering. The per-share exercise price of the warrants was $0.2701. The net proceeds resulting from the offering were up to $11.5 million and were utilized for general corporate purposes.
XCUR stock is 13% up year-to-date but losing momentum in Friday’s aftermarket trading as it announced the 2021 annual financial report. The company’s revenue and EPS declined drastically YoY and also did not meet the analysts’ expectations.